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Abstract
Gastrointestinal stromal tumors (GISt) are mesenchy-
mal  tumors  that  in  the  past  were  classified  as
leiomyosarcomas  or  leiomyomas  not  responding  to
standard  sarcoma  chemotherapy.  In  several  phase  I
and II trials the efficacy and safety of imatinib was
shown before the largest trial ever performed in a sin-
gle sarcoma entity revealed response rates (cR/PR) of
52 %. this multicenter phase II trial presented here
was performed to open access to imatinib for patients
with  unresectable  or  metastastatic  GISt  when  the
EoRtc 62005 trial had been closed before imatinib
was approved in Germany. It was designed to follow
the best clinical response and to assess the efficacy,
safety and tolerability of imatinib 400mg/d in patients
with  unresectable  or  metastatic  gastrointestinal  stro-
mal tumor.
95 patients were treated in this trial with Imatinib
400mg/d. four patients (4.6 %) attained a complete
response and 26 patients (29.9%) a partial response to
imatinib  treatment.  forty-one  patients  (47.1  %)  re-
vealed a stable disease and 16 patients (18.4 %) had a
progressive disease.
of the progressive patients 22% showed a partial
response and 67 % showed stable disease after escalat-
ing the dose to 800 mg. According to SwoG tumor
response classification, 66 patients (70%) were free of
progression within the first year of treatment.
Seventy-one  patients  (74.7%)  experienced  adverse
events or severe adverse events with a suspected rela-
tionship  to  the  study  drug.  Among  these,  the  most
common were nausea (n=27 patients, 28.4 %), eyelid
edema and peripheral edema in 23 patients each (24.2
%), diarrhea in 20 patients (21.1 %), muscle cramps in
15 patients (15.8 %) and fatigue in 13 patients (13.7
%).
Imatinib  400  mg/d  led  to  disease  stabilisation  in
81,6% of patients with unresectable or metastatic ma-
lignant GISt. thirty-four percent of patients attained
a tumor remission (partial or complete response). the
safety profile of imatinib based on adverse event as-
sessment is favorable. Imatinib is generally well toler-
ated in patients with gastrointestinal stromal tumors.
IntRoductIon
Gastrointestinal stromal tumors (GISt) are mesenchy-
mal  tumors  that  in  the  past  were  classified  as
leiomyosarcomas  or  leiomyomas  not  responding  to
standard sarcoma chemotherapy. Recently, GISt were
shown to share striking immunohistochemical similari-
ties with interstitial cells of cajal which are responsi-
ble for intestinal motility. In addition, gain of function
mutations of the KIt-receptor were found to be an
early and pre-eminent oncogenic event in the vast ma-
jority of GISt.  this has led to therapy with imatinib
mesylate, a highly selectively inhibitor of the protein
tyrosine kinase family comprising Abl, the chimeric
bcR-Abl, the platelet-derived growth factor (PdGf)
receptor α and β, and the product of the c-KIt pro-
to-oncogene (KIt) [1-3]. In several phase I and II tri-
als the efficacy and safety of imatinib was shown [4-7]
before the largest trial ever performed in a single sar-
coma entity revealed response rates (cR/PR) of 52 %
[8]. this multicenter phase II trial presented here was
performed to open access to imatinib for patients with
unresectable or metastastatic GISt when the EoRtc
62005 trial had been closed before imatinib was ap-
proved in Germany. 
PAtIEntS And MEtHodS
this multicenter open label clinical trial was designed
to follow the best clinical response and to assess the
efficacy, safety and tolerability of imatinib 400mg/d in
patients with unresectable or metastatic gastrointesti-
nal stromal tumor. Imatinib dose could be increased to
600 mg/d and then 800 mg/d if the patient did not
respond. for this purpose, 13 centers were recruited in
Germany that actively contributed to the enrollment
and assessment of study patients. In each center the
trial was approved by the local ethics committee.
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histological  diagnosis  of  unresectable  or  metastatic
GISt expressing c-KIt (cd117). lesions had to be
measurable  as  defined  by  Southwestern  oncology
Group Solid tumor Response criteria. Analysis of the
efficacy analyzable population was considered primary
for this evaluation, using re-calculated tumor surfaces.
Patients  were  allowed  to  have  received  previous
chemotherapy at least four weeks before study entry.
A performance status of 0-3 (EcoG) and adequate
total bilirubin < 1.5 x uln, SGot and SGPt < 2.5 x
unl (or < 5 x uln if hepatic metastases were pre-
sent),  creatinine  <  1.5  x  uln,  absolute  neutrophil
count > 1.5 x 109/l and platelets > 100 x 109/l were
required. the protocol was performed in accordance
with  the  declaration  of  Helsinki.  All  patients  gave
written informed consent. baseline assessment of the
primary status according to the SwoG response crite-
ria was scheduled within 14 days of first dose of study
drug. Patients received physical examinations, evalua-
tion  of  performance  status  and  measurements  of
body weight, complete blood count and serum chem-
istry regularly to monitor potential side effects of ima-
tinib accurately. tumor response was measured by ct
or MRI on days 1, 29, 85, 169, and 351 in relation to
baseline.
StAtIStIcS
frequency analyses are provided for the categories of
the overall best tumor response according to the defi-
nition of the SwoG (primary endpoint). confidence
intervals  (two-sided,  95%,  Pearson-clopper-limits)
were calculated for the rate of responders. In addition
to responder analysis, a benefit analysis was performed
which  included  also  patients  with  stable  disease  de-
fined as overall tumor response. Survival plots for pro-
gression  free  survival  and  overall  survival  (including
95% confidence intervals (cI) were calculated accord-
ing to Kaplan-Meier-method (secondary endpoints).
RESultS
A total of 95 patients were treated in this multi-center
trial between october 2001 (first patient enrolled) and
June 2003 (last patient completed). Patientsﾴ character-
istics are summarized in table 1. four patients were
judged  to  be  ineligible  for  evaluation  due  to  major
protocol violations, e.g. age < 18 years, no measurable
disease as well as two patients who were allocated to
surgical resection due to resectable tumor lesions. Re-
cruitment per study site varied between 1 patient and
22 patients. total study duration was 1.6 years (589
days or 19.4 months). Mean age was 59 years, ranging
from  18  to  80  years;  56  patients  were  male  (59%).
Mean time from initial diagnosis to start of therapy
was 17.4 months and in more than half of the patients
(62%), the index disease was recurrent or progressive.
the tumor stage diagnosed in most patients (41%) was
stage Iv. the majority of patients (n = 76, 80%) had
an EcoG performance status of grade 0 or 1. besides
gastrointestinal disorders (n = 19 patients, 20%), fre-
quent current medical conditions at time of start of
trial were vascular disorders (n = 26 patients, 27%,),
cardiac  disorders  (n  =  20  patients,  22%),  metabolic
and  nutrition  disorders  (n  =  18  patients,  19%)  and
psychiatric disorders (n = 16 patients, 17%).
A dose of 400 mg/day of imatinib was orally ap-
plied to 89 patients (94 %). furthermore, 8 patients (8
%) were treated with less than 400 mg/d, 9 patients
(10 %) took more than 400 mg/d, and 1 patient had
both dose reduction or interruption and dose escala-
tion,  each  regimen  for  at  least  4  weeks.  no  patient
took doses higher than 800 mg/d. treatment was in-
terrupted in 20 patients (22%) for an average duration
of 15.1 ﾱ 19.0 days (median 6 days, range 1-77 days).
dose escalations were performed in 9 patients (10 %).
none of these patients achieved a complete response.
but of the patients being progressive 22% showed a
partial response and 67 % showed stable disease after
escalating the dose to 800 mg. According to SwoG
tumor response classification, 66 patients (70%) were
free of progression within the first year of treatment.
Mean time to progression was 302 days (9.9 months).
the primary endpoint of the trial was overall re-
sponse rate (oRR) based on the SwoG solid tumor
response  criteria.  with  respect  to  overall  response,
81.6 % (71 patients) had at least a disease stabilisation.
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Table 1. Patients characteristics (n = 95).
Age (yrs)
Median 59
Range 18-80
Sex  (No)
Male 56
female 39
ECOG  (No)
Grade 0 36
Grade 1 40
Grade 2 17
Grade 3 2
Time since initial diagnosis (days)
Median 180
Range 0-6141
Disease Status (%)
Recurrence/Progression 62
Site of tumor (%)
Stomach 33
liver 28
Small intestine 23
Peritoneum 5
Rectum 5
colon 4
Esophagus 1
Pancreas 1
Table 2. Response to imatinib: (n = 87; n = 8 not assessable).
N pts (%)
complete response 4  (4.6)
Partial response 26 (29.9)
Stable disease 41 (47.1)
Progressive disease 16 (18.4)
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tients (29.9%) a partial response to imatinib treatment.
forty-one patients (47.1 %) revealed a stable disease
and  16  patients  (18.4  %)  had  a  progressive  disease
(table 2). 
SAfEty ASSESSMEnt
A total of 84 patients (88.4%) experienced at least a
single adverse event (AE), and in 74% of patients the
AE was judged as drug-related. the most common ad-
verse events were diarrhea (29% of patients), nausea
(27%), eyelid edema (23%), peripheral edema (22%),
muscle cramps (15%) and fatigue (13%). the majority
of these side effects were mild to moderate. the med-
ications  most  frequently  applied  for  relief  were
furosemide (24 patients), metamizole sodium (21 pa-
tients), metoclopramide (18 patients), allopurinol (16
patients), omeprazole (14 patients) as well as  potassi-
um chloride and actylsalicyclic acid (12 patients each).
Regardless of its relationship to the study drug ap-
plied,  adverse  events  were  severe  in  25  patients
(26.3%) and life-threatening in 7 patients (7.4%); in 10
of these patients (10.5%), severe adverse events were
considered to be related to the study medication. for
none of the life-threatening events such a relationship
was reported.
Seventy-one  patients  (74.7%)  experienced  adverse
events or severe adverse events with a suspected rela-
tionship to study drug. Among these, the most com-
mon were nausea (n = 27 patients, 28.4 %), eyelid ede-
ma and peripheral edema in 23 patients each (24.2 %),
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Table 3.1. number (%) of patients with adverse events, by body system and preferred term, by relation to study drug.
N = 95 Imatinib mesylate
not related related total
Gastrointestinal disorders 67 (70.5)
nausea 9 (9.5) 27 (28.4) 36 (37.9)
abdominal pain 23 (24.2) 4    (4.2)27  (28.4)
diarrhea 6 (6.3) 20 (21.1) 26 (27.4)
vomiting 8 (8.4) 9 (9.5) 17 (17.9)
constipation 10 (10.5) 4 (4.2) 14 (14.7)
flatulence 5 (5.3) 6 (6.3) 11 (11.6)
abdominal discomfort 8 (8.4) 2 (2.1) 10 (10.5)
dyspepsia 2 (2.1) 3 (3.2) 5 (5.3)
abdominal pain  2 (2.1) 2 (2.1) 4 (4.2)
subileus 4 (4.2) -- 4 (4.2)
melaena 3 (3.2) -- 3 (3.2)
stomatitis 3 (3.2) -- 3 (3.2)
General disorders  54 (56.8)
oedema peripheral 6 (6.3) 23 (24.2) 29 (30.5)
fatigue 9 (9.5) 13 (13.7) 22 (23.2)
oedema 1 (1.1) 9 (9.5) 10 (10.5)
pain 7 (7.4) 2 (2.1) 9 (9.5)
asthenia 3 (3.2) 6 (6.3) 9 (9.5)
fever 6 (6.3) 1 (1.1) 7 (7.4)
chest pain 3 3.2) -- 3 (3.2)
Musculoskeletal and connective tissue disorders 35 (36.8)
muscle cramp 2 (2.1) 15 (15.8) 17 (17.9)
arthralgia 8 (8.4) 2 (2.1) 10 (10.5)
pain (extremities) 6 (6.3) -- 6 (6.2)
back pain 4 (4.2) 1 (1.1) 5 (5.3)
myalgia 1 (1.1) 3 (3.2) 4 (4.2)
Skin and subcutaneous tissue disorders 34 (35.8)
periorbital oedema -- 8 (8.4) 8 (8.4)
exanthema 1 (1.1) 6 (6.3) 7 (7.4)
face oedema -- 6  (6.3) 6 (6.3)
hyperhidrosis 3 (3.2) 2 (2.1) 5 (5.3)
alopecia 1 (1.1) 2 (2.1) 3 (3.2)
dry skin -- 3 (3.2) 3 (3.2)
erythema -- 3 (3.2) 3 (3.2)
night sweats 2 (2.2) 1 (1.1) 3 (3.2)
pruritus -- 3 (3.2) 3 (3.2)
scar pain 3 (3.2) -- 3 (3.2)
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patients (15.8 %) and fatigue in 13 patients (13.7 %).
of the adverse events with suspected relationship to
the study drug, 10 patients (10.5 %) experienced se-
vere  adverse  events  but  none  was  life-threatening.
Anemia as an adverse event was found in 16 patients
(16.8%), in a single case grade III due to bleeding. In
11 patients (11.6%), dose was escalated to 600 or 800
mg/d for at least 4 weeks and in 17 patients (17.9%)
for at least 1 day. 
Regardingthe time since initial diagnosis of GISt,the
following events were seen more frequently in patients
with relatively longer presence of illness compared to a
shorter duration: fatigue (n = 8 vs. n = 5 patients), face
edema,  conjunctivitis,  elevation  of  lactate  dehydroge-
nase (ldH) (n = 4 vs. n = 2 patients each). It should;
however, be noted that subgroups were formed by me-
dian split, and the subgroups do not differ considerably.
Suspected  unexpected  non-serious  adverse  reac-
tions  considered  worth  mentioning  (as  recorded  in
EuRoPEAn JouRnAl of MEdIcAl RESEARcH May 12, 2011 209
Table 3.2. number (%) of patients with adverse events, by body system and preferred term, by relation to study drug.
N = 95 Imatinib mesylate
not related related total
Eye disorders 27 (28.4)
eyelid oedema -- 23 (24.2) 23 (24.2)
conjunctivitis -- 6 (6.3) 6 (6.3)
lacrimation increased -- 3 (3.2) 3 (3.2)
Nervous system disorders 23 (24.1)
dizziness 3 (3.2) 8 (8.4) 11 (11.6)
headache 6 (6.3) 3 (3.2) 9 (9.5)
paraesthesia -- 3 (3.2) 3 (3.2)
Blood and lymphatic system disorders 21 (22.1)
anaemia 7 (7.4) 9 (9.5) 16 (16.8)
leukopenia -- 4 (4.2) 4 (4.2)
Psychiatric disorders 19 (20.0)
insomnia 8 (8.4) 1 (1.1) 9 (9.5)
anxiety 5 (5.3) -- 5 (5.3)
depression 3 (3.2) 2 (2.1) 5 (5.3)
sleep disorder 2 (2.1) 2 (2.1) 4 4.2)
Metabolism and nutrition disorders 18 (19.0)
anorexia 7 (7.4) 4 (4.2) 11 (11.6)
hypokalaemia 6 (6.3) 1 (1.1) 7 (7.4)
hyperuricaemia 3 (3.2) -- 3 (3.2)
Infections  18 (19.0)
nasopharyngitis 6 (6.3) -- 6 6.3)
urinary tract infection 3 (3.2) -- 3 (3.2)
Respiratory, thoracic and mediastinal disorders 12 (12.6)
cough 4 (4.2) -- 4 (4.2)
pleural effusion 3 (3.2) -- 3 (3.2)
Vascular disorders 9 (9.5)
hypertension 4 (4.2) -- 4 (4.2)
Laboratory findings 37 (39.0)
blood lactate dehydrogenase increased 6 (6.3) 6 (6.3) 12 (12.6)
blood bililrubin increased 2 (2.1) 8 (8.4) 10 (10.5)
blood alkaline phosphatase increased 5 (5.3) 4 (4.2) 9 (9.5)
blood creatinine increased 2 (2.1) 6 (6.3) 8 (8.4)
blood urea increased 3 (3.2) 4 (4.2) 7 (7.4)
alanine aminotransferase (Alt) increased 2 (2.1) 4 (4.2) 6 (6.3)
aspartate aminotransferase (ASt) increased 2 (2.1) 4  (4.2) 6 (6.3)
blood uric acid increased 6 (6.3) -- 6 6.3)
haemoglobin decreased 1 (1.1) 4 (4.2) 5 (5.3)
hepatic enzyme increased 1 (1.1) 3 (3.2) 4 (4.2)
2) Schlemmer_Umbruchvorlage  21.04.11  15:22  Seite 209>3%  of  patients)  were  increase  in  blood  urea,  de-
crease in hemoglobin, and leucocytopenia. neutrope-
nia was not recorded at all. no suspected expected se-
rious  adverse  reactions  (SuSARs)  were  reported  in
this trial. ten patients (10.5%) with normal platelets at
baseline  shifted  outside  the  normal  range  at  end  of
treatment, and 16 patients (16.8%) shifted above the
leukocyte upper limit of normal. total protein was de-
creased  in  19  patients  (20.0%),  and  alkaline  phos-
phatase was increased in 11 patients (11.6%). no pa-
tient in our trial suffered from clinical cardiotoxicity,
as reported elsewere [10]. our findings support, that
imatinib does not induce cardiac toxicity even though
we did not monitor routineously cardiac function[11].
ncI/nHI common toxicity criteria (ctc) were
applied to all laboratory parameters, and shifts across
toxicity grades were evaluated in worst case analysis.
Shifts from baseline to end of treatment by at least 2
toxicity grades were seen in the following hematologi-
cal parameters: from grade 0 to grade 3 in lympho-
cytes count (n = 3 patients, 3.2%); shifts from grade 1
to grade 3 in hemoglobin (n = 2, 2.1%) and lympho-
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Table 4. number (%) of patients with non-hematological adverse events by severity and relationship to study drug.
N = 95 Grade 1 / 2 Grade 3 / 4
Preferred term total related Total related
nausea 34 (35.8) 26 (27.4) 2 (2.1) 1 (1.1)
oedema 8 (8.4) 8 (8.4) 2 (2.1) 1 (1.1)
oedema peripheral 29 (30.5) 23 (24.1) -- --
oedema genital 1 (1.1) 1 (1.1) --
Eyelid oedema 23 (24.2) 23 (24.2) -- --
face oedema 6 (6.3) 6 (6.3) -- --
Periorbital edema 8 (8.4) 8 (8.4) -- --
vomiting 12 (12.6) 8 (8.4) 5 (5.3) 1 (1.1)
Muscle cramp 17 (17.9) 15 (15.8) -- --
Muscle spasticity 2 (2.1) 1 (1.1) -- --
diarrhea 25 (26.3) 19 (20.0) 1 (1.1) 1 (1.1)
dermatitis allergic 1 (1.1) 1 (1.1) -- --
Rash 2 (2.1) 1 (1.1) -- --
Headache 8 (8.4) 2 (2.1) 1 (1.1) 1 (1.1)
Abdominal pain 24 (25.3) 4 (4.2) 3 (3.2) --
Arthralgia 9 (9.5) 2 (2.1) 1 (1.1) --
Fig. 1. Progression free surival.
2) Schlemmer_Umbruchvorlage  21.04.11  15:22  Seite 210cytes count (n = 1, 1.1%); shifts from grade 0 to grade
2 in lymphocytes count (n = 5, 5.3%) and hemoglobin
(n = 3, 3.2%). no increase in hematological toxicity
was  seen  in  basophils,  eosinophils,  and  monocytes.
(see table 4)
Shifts from baseline to end of treatment by at least
2  toxicity  grades  were  seen  in  the  following  non-
hematological parameters: from grade 0 to grade 3 in
creatinine (n = 1, 1.1%) and bilirubin (n = 1, 1.1%);
shifts  from  grade  1  to  grade  3  in  albumin  (n  =  1,
1.1%) and alkaline phosphatase (n = 1, 1.1%); shifts
from grade 0 to grade 2 in bilirubin (n = 3, 3.2%) 
and  albumin  (n  =  2,  2.1%).  no  increase  in  non-
hematological  toxicity  was  observed  in  blood  urea 
nitrogen,  total  protein,  or  lactate  dehydrogenase
(table 3.2).
worst  case  analysis  of  patients  with  normal  vital
signs at baseline and abnormal findings at the most
unfavorable post-baseline visit revealed abnormally in-
creased systolic blood pressure and bMI, each in 12
patients (12.6%). 
dIScuSSIon
the standard treatment of unresectable or metastatic
gastrointestinal stromal tumors is imatinib (Glivec) at
a dose of 400mg/d, since several studies have shown a
disease  control  rate  (cR,  PR,  Sd)  of  approximately
75% for this agent [12-14]. our trial showed a compa-
rable rate of 81% and a comparable cR rate of 4%.
cRs have been mainly observed in younger patients
not older than 58 years, but these patients did not dif-
fer  regarding  other  characteristics  e.g.  initial  tumor
stage or time since initial diagnosis. the rate of partial
response (29%) was lower in our study than previously
reported. one reason might be that the majority (62%)
of our patients suffered from recurrent or progressive
disease. 
Subgroup analysis of patients with partial response
including the performance status, time since initial di-
agnosis and dose regimen (dose stable vs. escalated)
showed that none of these variables made a difference
concerning disease control rate. 
the present data demonstrated that patients with
good performance status (EcoG 1 = 39%, EcoG 0
= 38%), were more likely to respond to therapy with
imatinib (Glivec). this is in accordance with prognos-
tic data published by the EoRtc StbSG [9]. 
Seventy-five patients (86.2 %) survived the first year
of  treatment.  Exploratory  analysis  suggests  that  pa-
tients with good performance status at baseline were
more likely to survive, both within the first year and
thereafter. According to tumor response, 66 patients
(75.8 %) were free of progression throughout the trial,
until end of treatment, and 62 of these (71.2%) were
progression-free  within  the  first  year  of  treatment.
our analysis suggests, that patients with good perfor-
mance status at baseline were more likely to attain a
sustained response to imatinib, which is translated to a
longer period of freedom of progression. 
during the present trial side effects were meticu-
lously screened, as experiences with imatinib mesylate
were limited. treatment with an oral drug in patients
with  abdominal  tumors,  most  of  them  after  major
surgery, caused gastrointestinal side effects in 70% of
patients. 45% of our patients suffered from gastroin-
testinal side effects related to imatinib and 25% had
gastrointestinal problems likely not to be related to the
drug  (see  table  3).  nausea,  vomiting  and  diarrhea
were  among  the  common  gastrointestinal  adverse
events. nausea could be improved by taking imatinib
during meals and together with 500 ml water. In case
of  ineffectiveness  metoclopramide  was  prescribed.
loperamide is a reasonable option to treat imatinib-re-
lated  diarrhea.  commonly  observed  were  periorbital
edema,  peripheral  edema  in  the  lower  legs,  muscle
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Fig. 2. overall surival.
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cramps and fatigue. by monitoring body weight closely
and introducing diuretics and fluid retention these side
effects could be limited. Muscle cramps responded in
some cases to calcium and magnesium supplemention.
overall, drug-related side effects were severe in a small
proportion of patients (<2%) except for vomiting and
abdominal pain both occurring in 5.3% and 3.2% of
the study population. no life-threatening events have
been observed. In more than 95%, side effects due to
imatinib could be managed with standard concomitant
drugs,  such  as  furosemide,  metoclopamide,  metami-
zole and omeprazole. After one year of treatment, in
50 patients (54.9%) the performance status had been
improved or at least maintained compared to baseline
assessment. during treatment with imatinib, 81,6% of
patients  with  unresectable  or  metastatic  malignant
GISt revealed at least disease stabilisation. thirty-four
percent of patients attained a tumor remission (partial
or complete response). the safety profile of imatinib
based on adverse event assessment is favorable. Ima-
tinib is generally well tolerated in patients with gas-
trointestinal stromal tumors. Patients with good per-
formance status tolerate the imatinib even better. the
recognition of side effects is mandatory to further de-
velop an appropriate therapeutic management to relief
the drug-related symptoms. this is particularly impor-
tant at doses above 400 mg/d since it became evident
that subgroups of patients benefit from a higher initial
starting dose of imatinib in the first-line setting and
that patients with progressive disease during standard
dose should be escalated [15].
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